Related Experiment Videos
[Lithium, pregnancy and breast feeding]
A Villeneuve1, C Lajeunesse, A Pires
1Département de Psychiatrie, Faculté de Médecine, Université Laval, Québec, Canada.
L'Encephale
|March 1, 1989
Summary
Lithium use during pregnancy and breastfeeding poses risks, particularly cardiovascular malformations like Ebstein's anomaly. While generally avoided in the first trimester, lithium therapy may continue if necessary, with informed patient consent regarding potential risks.
Area of Science:
- Pharmacology
- Teratology
- Maternal-Fetal Medicine
Context:
- Lithium administration during pregnancy and postpartum requires careful consideration due to teratogenic potential and excretion into breast milk.
- Understanding lithium's pharmacokinetic changes during pregnancy is crucial for managing maternal and fetal health.
Purpose:
- To review the kinetics of lithium during pregnancy.
- To assess the influence of lithium on the fetus during pregnancy and breastfeeding.
- To outline management strategies for lithium therapy in pregnant and breastfeeding individuals.
Summary:
- Lithium exposure in utero can lead to congenital malformations, most notably Ebstein's anomaly, affecting the cardiovascular system.
- While lithium is generally contraindicated during the first trimester of pregnancy, it may be continued if essential for maternal health.
- Informed consent is paramount, ensuring patients understand the risks associated with lithium use during pregnancy and lactation.
Impact:
- Provides critical information for clinicians managing patients on lithium therapy who are pregnant or breastfeeding.
- Highlights the importance of risk-benefit assessment and patient counseling in lithium treatment during sensitive reproductive periods.
- Contributes to the understanding of lithium's teratogenic effects and informs clinical guidelines for its use in obstetrics and gynecology.